A nation-wide survey of patients with homozygous familial hypercholesterolemia phenotype undergoing LDL-apheresis in Turkey (A-HIT 1 registry)
Makaleler > Tam Makale · 2018
Yazarlar: Latife Meral KAYIKÇIOĞLU, Lale Tokgozoglu, Mehmet Yilmaz, LEYLAGÜL KAYNAR, Melih Aktan, Rana Berru Durmus, Cumali Gokce, Ahmet Temizhan, OSMAN İLHAMİ ÖZCEBE, Tulay Karaagac Akyol, Harika Okutan, Saim Sag, Ozen Oz Gul, Zafer Salcioglu, Mustafa Yenercag, Bulent B. Altunkeser, Irfan Kuku, Hamiyet Yilmaz Yasar, Erdal Kurtoglu, Melis Demir Kose, Sinan Demircioglu, Zafer Pekkolay, Osman Ilhan
Atherosclerosis, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Wos, 2018, cilt 270, ss 42-48
DOI: 10.1016/j.atherosclerosis.2018.01.034
Özet
Background and aims: Homozygous familial hypercholesterolemia (HoFH) is a genetic condition characterized by lethally high levels of low-density lipoprotein cholesterol (LDL-C) from birth, and requires rapid and aggressive intervention to prevent death due to coronary heart disease and/or atherosclerosis. Where available, lipoprotein apheresis (LA) is the mainstay of treatment to promote survival.